Oncology, Streamlined R&D Will Help Pfizer Going Forward

We believe that most of the revenue growth will be driven by the expected ramp-up in the company's oncology drug sales. This will be complemented by a slight moderation in R&D (research and development) expenses, unlocking some value for shareholders.